

# HEALTHY U CHIP

## PRIOR AUTHORIZATION REQUEST FORM

### RHEUMATOID ARTHRITIS

Avsola®, Cimzia®, Enbrel®, Hadlima™, Humira®, Inflectra®, Kevzara®, Kineret®, Olumiant®, Orenzia®, Remicade®, Renflexis®, Riabni®, Rinvoq®, Rituxan®, Ruxience®, Simlandi®, Simponi®, Truxima®, Tyenne®, Xeljanz®/XR

**For authorization, please answer each question and fax this form PLUS chart notes back to the Healthy U CHIP Prior Authorization Department.**

- For **Medical Pharmacy** please fax requests to: 801-213-1547
- For **Retail Pharmacy** please fax requests to: 385-425-4052

**Failure to submit clinical documentation to support this request will result in a dismissal of the request.**

If you have prior authorization questions, please call for Pharmacy Customer Service for assistance at 385-425-5094

Disclaimer: Prior authorization request forms are subject to change in accordance with Federal and State notice requirements.

Date:	Member Name:	ID#:
DOB:	Gender:	Physician:
Office Phone:	Office Fax:	Office Contact:
Height/Weight:		HCPCS Code:

**Member must try at least two formulary preferred drugs before a request for a non-formulary drug may be considered. If treatment with preferred products has not been successful, you must submit which preferred products have been tried, dates of treatment, and reason for failure. Reasons for failure must meet the Health Plan medical necessity criteria.**

#### Preferred/Non-Formulary:

##### 1. 1<sup>st</sup> Line Preferred Agents:

- Hadlima™ (adalimumab-bwvd), Simlandi® (adalimumab-ryvk)
- Infliximab products: Avsola® (infliximab-axxq), Inflectra® (infliximab-dyyb), infliximab, Remicade (infliximab), Renflexis® (infliximab-abda)
- Rituximab biosimilar products: Riabni® (rituximab-arrr), Ruxience® (rituximab-pvvr), Truxima® (rituximab-abbs)

##### 2. 2nd line preferred agents with single step; after trial and failure of BOTH Hadlima™ or Simlandi®, and a preferred infliximab agent:

- Cimzia® (certolizumab), Humira® (adalimumab), Kevzara® (sarilumab), Kineret® (anakinra), Olumiant® (baricitinib), Orenzia® (abatacept), Tyenne® (tocilizumab-aazg), Xeljanz/XR® (tofacitinib)

##### 3. Non-Formulary Agents with a triple step; after trial and failure of Hadlima™ or Simlandi®, and a preferred infliximab agent, and 2 second line agents:

- Enbrel® (etanercept), Rinvoq® (upadacitinib), Simponi® (golimumab)

Product being requested: \_\_\_\_\_

Dosing/Frequency: \_\_\_\_\_

#### If the request is for reauthorization, proceed to reauthorization section

Questions	Yes	No	Comments/Notes
1. Is the requesting provider a rheumatologist or in consultation with a rheumatologist?	<input type="checkbox"/>	<input type="checkbox"/>	
2. Is the member's condition moderate to severe based on the Disease Activity Score (DAS28) or is a tender and swollen joint count provided as well as C-reactive protein (CRP) or erythrocyte sedimentation rate (ESR)?	<input type="checkbox"/>	<input type="checkbox"/>	<b>Please provide documentation</b>

3. Has the member had an adequate trial and failure of at least one disease modifying antirheumatic drug (DMARD) (e.g. hydroxychloroquine, leflunomide, methotrexate, sulfasalazine) or contraindication to all? a. If oral methotrexate is not tolerated, intramuscular or subcutaneous methotrexate must be tried	<input type="checkbox"/>	<input type="checkbox"/>	<b>Please provide documentation</b>
4. If the request is for Rinvoq, Olumiant, or Xeljanz/XR, does documentation show inadequate response or intolerance to at least one TNF (tumor necrosis factor) blocker such as an infliximab product, Cimzia, an adalimumab product and/or Simponi and does documentation show the member will not be receiving Rinvoq, Olumiant, or Xeljanz/XR in combination with a potent immunosuppressant (e.g., azathioprine or cyclosporine)?	<input type="checkbox"/>	<input type="checkbox"/>	<b>Please provide documentation</b>
5. If the request is for a Tumor Necrosis Factor Inhibitor or an Interleukin Receptor Antagonist, has the provider performed tuberculosis (TB) screening prior to therapy initiation?	<input type="checkbox"/>	<input type="checkbox"/>	<b>Please provide documentation</b>
6. If the request is for a Tumor Necrosis Factor Inhibitor, has the provider performed hepatitis B screening prior to therapy initiation?	<input type="checkbox"/>	<input type="checkbox"/>	<b>Please provide documentation</b>
<b>REAUTHORIZATION</b>			
1. Is the request for reauthorization of therapy?	<input type="checkbox"/>	<input type="checkbox"/>	
2. Has the member experienced at least a 20% improvement in ACR or DAS28 score since therapy initiation?	<input type="checkbox"/>	<input type="checkbox"/>	<b>Please provide documentation</b>
3. Has the provider performed continued tuberculosis monitoring during therapy?	<input type="checkbox"/>	<input type="checkbox"/>	<b>Please provide documentation</b>
4. Has the provider performed continued Hepatitis B monitoring in HBV carriers?	<input type="checkbox"/>	<input type="checkbox"/>	<b>Please provide documentation</b>
<b>What medications and/or treatment modalities have been tried in the past for this condition? Please document name of treatment, reason for failure, treatment dates, etc.</b>			
Additional information:			
Physician's Signature:			

**\*\* Failure to submit clinical documentation to support this request will result in a dismissal of the request.\*\***

Policy: PHARM-CHIP-065  
 Origination Date: 07/01/2024  
 Reviewed/Revised Date: 11/13/2024  
 Next Review Date: 11/13/2025  
 Current Effective Date: 12/01/2024

**Confidentiality Notice**

This document and any accompanying document contain confidential information and is intended for the use of the individual or entity named on this transmission sheet. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or the taking of any action in reliance on the contents of this information is strictly prohibited and the document should be returned to this office immediately. If you have received this facsimile in error, please notify us by telephone immediately and destroy document received.